is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
Click for full image >>
TG Therapeutics Announces Completion of Enrollment and B-cell Depletion Data from Part 1 of Ongoing Phase 2 Multiple Sclerosis Study
TG Therapeutics Announces Orphan Drug Designation for the Combination of TG-11101 and TGR-1202 for the treatment of Chronic Lymphocytic Leukemia
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group